270 related articles for article (PubMed ID: 30825015)
21. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
Villaruz LC; Socinski MA
Clin Pharmacol Ther; 2016 Sep; 100(3):212-4. PubMed ID: 27090296
[TBL] [Abstract][Full Text] [Related]
22. Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with clinical outcome of erlotinib treatment.
Wang YS; Miao LY; Liu L; Cai HR; Ding JJ; Ren SX; Zhou CC; Schmid-Bindert G
Chin Med J (Engl); 2013 Oct; 126(20):3931-5. PubMed ID: 24157160
[TBL] [Abstract][Full Text] [Related]
23. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
24. Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient.
Biondani P; De Martin E; Samuel D
Ann Oncol; 2018 Jan; 29(1):286-287. PubMed ID: 29293878
[No Abstract] [Full Text] [Related]
25. C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients.
Patil NS; Zou W; Mocci S; Sandler A; Ballinger M; Flynn S; Kowanetz M; Hegde PS
PLoS One; 2021; 16(2):e0246486. PubMed ID: 33534859
[TBL] [Abstract][Full Text] [Related]
26. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
[TBL] [Abstract][Full Text] [Related]
27. Clinical Application of Iodine-125 Seed Brachytherapy Combined with Anti-PD-1 Antibodies in the Treatment of Lung Cancer.
Sui A; Song H; Yu H; Zhang H; Hu Q; Lei Y; Zhang L; Wang J
Clin Ther; 2020 Aug; 42(8):1612-1616. PubMed ID: 32646546
[TBL] [Abstract][Full Text] [Related]
28. Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer.
Ottonello S; Genova C; Cossu I; Fontana V; Rijavec E; Rossi G; Biello F; Dal Bello MG; Tagliamento M; Alama A; Coco S; Boccardo S; Vanni I; Ferlazzo G; Moretta L; Grossi F; Mingari MC; Carrega P; Pietra G
Front Immunol; 2020; 11():125. PubMed ID: 32117275
[TBL] [Abstract][Full Text] [Related]
29. Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer.
Katsurada M; Nagano T; Tachihara M; Kiriu T; Furukawa K; Koyama K; Otoshi T; Sekiya R; Hazama D; Tamura D; Nakata K; Katsurada N; Yamamoto M; Kobayashi K; Nishimura Y
Anticancer Res; 2019 Feb; 39(2):815-825. PubMed ID: 30711962
[TBL] [Abstract][Full Text] [Related]
30. The clinical significance of soluble PD-1 and PD-L1 in lung cancer.
Abu Hejleh T; Furqan M; Ballas Z; Clamon G
Crit Rev Oncol Hematol; 2019 Nov; 143():148-152. PubMed ID: 31675543
[TBL] [Abstract][Full Text] [Related]
31. Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer.
Takeda T; Takeuchi M; Saitoh M; Takeda S
Thorac Cancer; 2018 Oct; 9(10):1291-1299. PubMed ID: 30126063
[TBL] [Abstract][Full Text] [Related]
32. HTLV-1 seropositive patients with lung cancer treated with PD-1 inhibitors.
Yoneshima Y; Kato K; Minami H; Ikeda M; Watanabe H; Yoshimoto G; Miyamoto T; Akashi K; Nakanishi Y; Okamoto I
Cancer Sci; 2020 Sep; 111(9):3395-3396. PubMed ID: 32557883
[No Abstract] [Full Text] [Related]
33. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
Lupo A; Alifano M; Wislez M; Boulle G; Velut Y; Biton J; Cremer I; Goldwasser F; Leroy K; Damotte D
Rev Pneumol Clin; 2018 Oct; 74(5):339-350. PubMed ID: 30337201
[TBL] [Abstract][Full Text] [Related]
34. Targeting immune checkpoints in non small cell lung cancer.
Bianco A; Malapelle U; Rocco D; Perrotta F; Mazzarella G
Curr Opin Pharmacol; 2018 Jun; 40():46-50. PubMed ID: 29525401
[TBL] [Abstract][Full Text] [Related]
35. Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer?
Cheng M; Durm G; Hanna N; Einhorn LH; Kong FS
Future Oncol; 2017 Dec; 13(28):2503-2505. PubMed ID: 29168656
[No Abstract] [Full Text] [Related]
36. Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis.
Yamaguchi T; Shimizu J; Hasegawa T; Horio Y; Inaba Y; Yatabe Y; Hida T
Lung Cancer; 2018 Nov; 125():212-217. PubMed ID: 30429022
[TBL] [Abstract][Full Text] [Related]
37. Research on the relationship between serum levels of inflammatory cytokines and non-small cell lung cancer.
Song XY; Zhou SJ; Xiao N; Li YS; Zhen DZ; Su CY; Liu ZD
Asian Pac J Cancer Prev; 2013; 14(8):4765-8. PubMed ID: 24083740
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan.
Hsu JC; Lin JY; Hsu MY; Lin PC
PLoS One; 2018; 13(8):e0202725. PubMed ID: 30142174
[TBL] [Abstract][Full Text] [Related]
39. Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer.
Carbone F; Grossi F; Bonaventura A; Vecchié A; Minetti S; Bardi N; Elia E; Ansaldo AM; Ferrara D; Rijavec E; Dal Bello MG; Biello F; Rossi G; Tagliamento M; Alama A; Coco S; Spallarossa P; Dallegri F; Genova C; Montecucco F
Clin Exp Metastasis; 2019 Oct; 36(5):449-456. PubMed ID: 31376097
[TBL] [Abstract][Full Text] [Related]
40. A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer.
Guisier F; Cousse S; Jeanvoine M; Thiberville L; Salaun M
Sci Rep; 2019 Nov; 9(1):16902. PubMed ID: 31729430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
